Glomerulosclerosis, Focal Segmental: Clinical Trials

16 trials for Glomerulosclerosis, Focal Segmental, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 recruiting, 2 terminated, 1 unknown. 16 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 10, Recruiting 2, Terminated 2, Unknown 1, Withdrawn 1
Phase 22Completed 1, Recruiting 1

Follow Glomerulosclerosis, Focal Segmental: new trials by email Literature Review of Glomerulosclerosis, Focal Segmental trials Research Report on Glomerulosclerosis, Focal Segmental

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment
IXP - Focal Segmental Glomerulosclerosis (FSGS)
Phase 1CompletedVertex Pharmaceuticals Incorporated362024-08-022025-01-20
AMPK-activation by Metformin in FSGS: AMP-FSGS
Metformin + Standard of Care, Placebo + Standard of Care - Focal Segmental Glomerulosclerosis
Phase 1 / Phase 2RecruitingYale University302023-12-142026-02-03
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
VX-147 - Focal Segmental Glomerulosclerosis (FSGS)
Phase 1CompletedVertex Pharmaceuticals Incorporated212023-07-192023-09-13
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
HS-10390 tablet, Placebo tablet - IgA Nephropathy, Focal Segmental Glomerulosclerosis
Phase 1RecruitingHansoh BioMedical R&D Company842023-05-232024-10-09
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
ALXN1720 - Proteinuria
Phase 1CompletedAlexion Pharmaceuticals, Inc.132022-06-292023-06-29
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
RE-021, sparsentan - Healthy Subjects
Phase 1CompletedTravere Therapeutics, Inc.472020-06-182022-09-30
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
GFB-887, Placebo - Healthy Volunteers
Phase 1CompletedGoldfinch Bio, Inc.702019-05-292020-06-02
Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis
Bone marrow stem cell - Focal Segmental Glomerulosclerosis, Chronic Kidney Diseases
Phase 1CompletedUniversidade Federal do Rio de Janeiro52015-06-252020-01-28
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
Intravenous injection - Focal Segmental Glomerulosclerosis
Phase 1UnknownRoyan Institute52015-05-012015-12-04
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
Galactose - Focal Segmental Glomerulosclerosis
Phase 1WithdrawnNorthwell Health2008-12-012015-09-07
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
Galactose - Focal Segmental Glomerulosclerosis
Phase 1TerminatedNorthwell Health152008-12-012015-09-10
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
FG-3019 - Focal Segmental Glomerulosclerosis
Phase 1TerminatedKyntra Bio22008-04-012019-07-31
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
GC1008 - Focal Segmental Glomerulosclerosis
Phase 1CompletedGenzyme, a Sanofi Company162007-05-012014-03-19
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
Rosiglitazone (Avandia), Adalimumab (Humira) - Focal Glomerulosclerosis
Phase 1CompletedNorthwell Health212005-07-012007-10-22
Permeability Factor in Focal Segmental Glomerulosclerosis
Plasma exchange, Cyclophosphamide - Focal Segmental Glomerulosclerosis
Phase 1 / Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)152000-12-012016-02-10
Total Lymphoid Irradiation (TLI) to Prevent Focal Segmental Glomerulosclerosis (FSGS)Recurrence in the Renal Graft
Total Lymphoid irradiation - Glomerulosclerosis, Focal
Phase 1CompletedUniversity of Sao Paulo102000-01-012006-07-18

Narrower conditions

Glomerulonephritis, IGA (3)  ·  Proteinuria (3)  ·  Diabetic Nephropathies (2)  ·  Nephrosis, Lipoid (2)  ·  Renal Insufficiency, Chronic (2)  ·  Diabetes Complications (1)  ·  Endocrine System Diseases (1)  ·  Glomerulonephritis (1)  ·  Glomerulonephritis, Membranoproliferative (1)  ·  Hematuria, Benign Familial (1)  ·  Kidney Diseases (1)  ·  Lupus Nephritis (1)  ·  Nephritis (1)  ·  Nephrosis (1)

Broader conditions

Female Urogenital Diseases (16)  ·  Female Urogenital Diseases and Pregnancy Complications (16)  ·  Male Urogenital Diseases (16)  ·  Urogenital Diseases (16)  ·  Glomerulonephritis (15)  ·  Kidney Diseases (15)  ·  Nephritis (15)  ·  Urologic Diseases (15)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Autoimmune Diseases (3)  ·  Disease Attributes (3)  ·  Immune System Diseases (3)  ·  Pathologic Processes (3)  ·  Signs and Symptoms (3)  ·  Urination Disorders (3)

Interventions

Galactose (2)  ·  Adalimumab (1)  ·  Bone Marrow Purging (1)  ·  Cyclophosphamide (1)  ·  Injections, Intravenous (1)  ·  Metformin (1)  ·  Plasma Exchange (1)  ·  Plasmapheresis (1)  ·  Rosiglitazone (1)  ·  Standard of Care (1)  ·  fresolimumab (1)  ·  pamrevlumab (1)  ·  sparsentan (1)

Sponsors

Northwell Health (3)  ·  Vertex Pharmaceuticals Incorporated (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Genzyme, a Sanofi Company (1)  ·  Goldfinch Bio, Inc. (1)  ·  Hansoh BioMedical R&D Company (1)  ·  Kyntra Bio (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Royan Institute (1)  ·  Travere Therapeutics, Inc. (1)  ·  Universidade Federal do Rio de Janeiro (1)  ·  University of Sao Paulo (1)  ·  Yale University (1)

Countries

United States (9)  ·  Brazil (2)  ·  United Kingdom (2)  ·  China (1)  ·  Germany (1)  ·  Iran (1)  ·  Italy (1)  ·  South Korea (1)

Top investigators

Howard Trachtman, MD (3)  ·  Cijiang He (1)  ·  Debbie Gipson, MD (1)  ·  Hamid Gourabi, PhD (1)  ·  Hassan Otukesh, MD (1)  ·  Jeanelle Kam, MD (1)  ·  Jeffrey B Kopp, M.D. (1)  ·  Madhav Menon, MD (1)  ·  Marcelo Marcos Morales, MD,PHD (1)  ·  Nasser Aghdami, MD,PhD (1)  ·  Pedro Chocair, Prof. PhD (1)  ·  Rosangela Villar, MD (1)  ·  Rozita Hosseini, MD (1)  ·  Soroosh Shekarchian, MD (1)

Results publications

PMID 35224732, PMID 39015674, PMID 40337980, PMID 41805697